Biotechs and nuclear power for AI in play today 📈

& Morning Brew

Good day, 360!

Here are some of our top movers today. And don’t forget to join us in Market Masters – the hottest trading room around 🔥. Be the best prepared trader on the Street!

---

FOCUS LIST🔎

PLRZ – Up over 200% in the pre-market after announcing it’s moving forward with expected 2025 clinical trial – entered manufacturing agreement for its PL-14 allergy blocker

CGTX – Up over 70% in the pre-market after announcing positive results in Phase 2 study of CT1812 in dementia with Lewy Bodies

OKLO – Up over 10% in pre after announcing partnership with Switch to form landmark strategic relationship to deploy 12 gigawatts of advanced nuclear power, one of the largest corporate clean power agreements ever signed

---

---

HOTLIST🔥

PLRZ – Up over 200% in the pre-market after announcing it’s moving forward with expected 2025 clinical trial – entered manufacturing agreement for its PL-14 allergy blocker

Polyrizon Ltd. (PLRZ) is a biotech company that engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

In the pre-market this morning, the company announced that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based Good Manufacturing Practice (GMP) manufacturer. This collaboration will supply Clinical Trial Material (CTM) for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025.

The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts.

Shares of PLRZ traded up 200% in the pre-market in reaction to the news.

The $2.90 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $3.20, $3.50, $3.89 and then the pre-market high at $4.15. Beyond that is blue sky all-time highs.

Below $2.90, targets to the downside are $2.30, $2.10, $1.80, $1.40 and then a gap fill at $1.05.

---

CGTX – Up over 70% in the pre-market after announcing positive results in Phase 2 study of CT1812 in dementia with Lewy Bodies

Cognition Therapeutics Inc. (CGTX) is a clinical-stage biopharmaceutical company that engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

In the pre-market this morning the company announced topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB).

Highlights from the study include:

– Improvements Across Measures of Behavior, Function, Cognition and Movement –

– Expediting Plans to Advance CT1812 into Late-Stage Trials –

– Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) –

Shares of CGTX traded up over 70% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $1.24. Above that, targets to the upside are a gap fill at $1.33, $1.70, $2 and $2.54.

Below $1.24, targets to the downside are $1.10, $1, $0.90, $0.70, $0.60, $0.50 and then a gap fill at $0.4549. 

---

---

OKLO – Up over 10% in pre after announcing partnership with Switch to form landmark strategic relationship to deploy 12 gigawatts of advanced nuclear power, one of the largest corporate clean power agreements ever signed 

Oklo Inc. (OKLO) designs and develops fission power plants to provide reliable and commercial-scale energy to customers in the United States.

In the pre-market this morning, the company announced a partnership with Switch, a premier provider of AI, cloud and enterprise data centers. The two companies have signed a non-binding Master Power Agreement (“Master Agreement”) to deploy 12 gigawatts of Oklo Aurora powerhouse projects through 2044. 

This is one of the largest corporate clean power agreements ever signed. The Master Agreement establishes a framework for collaboration, with the expectation that individual binding agreements will be finalized as project milestones are reached.

Shares of OKLO traded up over 10% in the pre-market in reaction to the news.

The $21.10 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $21.50 and then the pre-market high at $21.87. Beyond that $22.50, $23 and $24 come into play.

Below $21.10, targets to the downside are $20.70, $20.50, $20.20. $20, $19.67 and then a gap fill at $19.10.

---

MARKET NEWS 📰

P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas

---